Register


Create a profile to access all of our events, including options to sign up for our in person meetings and to view the online content from our past conferences!


Video Platform

View all the content from the last 12 months

MD Newsletter

Stay up to date with everything MD Education

Tickets & Events

Save your space and register for our future events

Select what applies to you




Login

Gaining access to MD Education’s premium offerings is only a button away! Enter your email and password to get educated.

MD-Education logo
Register / Login
We're evolving!

The website is currently being upgraded to include our new suite of offerings. Check back at the end of the month for a breakdown of our new services!


Questions? Contact us at:


office@md-education.com

Want Cookies?


Currently, we're using cookies for tracking purposes. By tracking, we mean what pages of MD Education you visit, what forms you submit and how you interact with our site. We do not sell this data to anybody. Currently, the Cookies we use are needed to collect form data through HubSpot.


If you'd like to see what we do with your data, head over to our Privacy Policy


3rd Annual

Thank you for registering to our ASH Satillite Symposium!

Please check your emails for registration confirmation.


CAR-T & Bispecifics

US Focus Meeting

Updating Knowledge & Clinical Practice in 2025


Kimpton Marlowe Hotel, Massachusetts

Friday, March 7, 2025 - Saturday, March 8, 2025

Presentations will be available online for 12 months

Meeting content distributed to 12,000+ HCPs

For more information get in touch!

=

Co-chair

Nitin Jain, MD

MD Anderson Cancer Center, Houston, TX

=

Co-chair

Noopur Raje, MD

Massachusetts General Hospital, Boston, MA

=

Co-chair

Sattva Neelapu, MD

MD Anderson Cancer Center, Houston, TX

Dear Colleagues and Friends,


We are delighted to extend our warmest invitation to the multinational congress CAR-T & Bispecifics US Focus 2025, to be held at Kimpton Marlowe Hotel, Massachusetts on the 7th of March, 2025.


This meeting provides pivotal collaboration aimed at advancing CAR-T & Bispecifics research and patient treatment.


This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts from around the world.


Engage in riveting presentations, participate in thought-provoking debates, round-table discussions, and connect with peers at informal social gatherings.


All meeting content will be accessible online for a full year, reaching an extensive audience of healthcare professionals worldwide.


People stood in a circle, smiling, with a cup of water

Agenda & Faculty

CAR-T & Bispecifics US Focus Meeting, Friday, March 7, 2025 - Saturday, March 8, 2025

7:30 AM

Registration Opens

8:20 AM

Opening Remarks – Ryan Fitzpatrick, CEO, MD Education

8:30 AM

Keynote Speaker; Mechanisms of Resistance to CAR-T Cell Therapy

=

Marco Ruella, MD

University of Pennsylvania, PA

Session 1: Myeloma Part I

8:50 AM

Sequencing of Bispecifics and CAR-T Cells

=

Amrita Krishnan, MD

City of Hope, Duarte, CA

9:10 AM

Moving Bispecifics and CAR-T Cells Early in Myeloma

=

Adam Sperling, MD

Dana-Farber Cancer Institute, Boston, MA

9:30 AM

Challenges with Access to CAR-T Cells in the Real World

=

Ben Derman, MD

University of Chicago Medical Center, Chicago, IL

9:50 AM

Panel Discussion

10:10 AM

Coffee Break

Session 2: Myeloma Part II

10:30 AM

Use of T-Cell Redirected Therapies in Smoldering Multiple Myeloma

=

Irene Ghobrial, MD

Dana-Farber Cancer Institute, Boston, MA

10:50 AM

Practical Considerations: Long-term Toxicities and Supportive Care with T-Cell Redirected Therapies

=

Krina Patel, MD

MD Anderson Cancer Center, Houston, TX

11:10 AM

Novel T-Cell Redirected Therapies in Myeloma

=

Sham Mailankody, MD

Memorial Sloan Kettering Cancer Center, NY

11:30 AM

Panel Discussion

11:50 AM

Lunch Break + Faculty and Fellow Photo

12:40 PM

Industry Supported Independent Expert Discussion

1:25 PM

Keynote Speaker; Pharmacovigilance for CAR-T Cell Therapies: What Have we Learnt?

=

Meghna Alimchandani, MD

Food and Drug Administration, Division of Pharmacovigilance

Session 3: Lymphoma Part I

1:45 PM

When to Use CAR-T vs Bispecifics in LBCL

=

Paolo Strati, MD

MD Anderson Cancer Center, Houston, TX

2:05 PM

When to Use CAR-T vs Bispecifics in Follicular Lymphoma

=

Carla Casulo, MD

University of Rochester, NY

2:25 PM

When to Use CAR-T vs Bispecifics in MCL

=

Tycel Phillips, MD

City of Hope, Duarte, CA

2:45 PM

Panel Discussion

3:05 PM

Coffee Break

Session 4: Lymphoma Part II

3:25 PM

CAR-T and Bispecific Options for T-cell Lymphomas

=

Swami P. Iyer, MD

MD Anderson Cancer Center Houston, TX

3:45 PM

Administering CAR-T and Bispecifics in the Outpatient Setting

=

Yi Lin, MD

Mayo Clinic, Rochester, MN

4:05 PM

Novel Autologous CAR-T Cell Therapies in NHL

=

Matthew Frank, MD

Stanford University, CA

4:25 PM

Allogeneic Cell Therapies in NHL

=

Caron Jacobson, MD

Dana-Farber Cancer Institute, Boston, MA

4:45 PM

Panel Discussion

5:05 PM

Adjourn